bempikibart (ADX-914)
Phase 2Small molecule
bempikibart (ADX-914) is one of 34 small molecule programs targeting Alopecia Areata. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Alopecia Areata
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Otezla
AmgenApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Zolymbus
AbbVieApproved
Daliresp
AstraZenecaApproved
Xeljanz
PPrism Pharmaceuticals
Approved
Anzupgo
Jazz PharmaceuticalsApproved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Zocor
OOrganon and Co
Approved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for bempikibart (ADX-914). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- QQ32 Bio Inc.